Key result
Verapamil selectively binds alpha-adrenergic receptors across tissues, unlike diltiazem and nifedipine.
Answers are grounded in this paper and cite their sources.
To determine the specificity of the previously demonstrated competition of verapamil with radioligand binding to alpha-adrenergic receptors, we examined the interaction of calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors on several tissues. Verapamil competed for [3H] prazosin binding to alpha 1-adrenergic receptors and for [3H]yohimbine binding to alpha 2-adrenergic receptors in several tissues (human platelets, rat kidney and heart, and cultured muscle cells) with dissociation constants of 0.6-6 microM. The calcium channel blockers D600, D591, fendiline, and prenylamine--which are structural analogues of verapamil--also competed for [3H]yohimbine binding to human platelets. Two other calcium channel blockers, diltiazem and nifedipine, did not compete for [3H] yohimbine binding to human platelets or [3H]prazosin binding to membranes prepared from rat ventricles. We used [3H]nitrendipine binding to identify putative calcium channels on rat myocardial membranes. Nifedipine and verapamil blocked these [3H]nitrendipine-binding sites on ventricular membranes, but epinephrine and prazosin did not, indicating that the ventricular alpha 1 receptors and calcium channels are distinct. We found no specific [3H]nitrendipine binding to human platelets. We conclude that the interaction of verapamil with alpha-adrenergic receptors is not receptor subtype or tissue specific, that interaction with alpha-adrenergic receptors is not a property of all calcium channel blockers, and that the interaction of verapamil with alpha-adrenergic receptors and its interaction with calcium channels occur at at least two distinct sites.
No takes yet. Share an insight, caveat, or question.
Motulsky et al. (1983) studied this question. Verapamil and other calcium channel blockers (D600, D591, fendiline, prenylamine, diltiazem, nifedipine) was evaluated on Competition for radioligand binding ([3H]prazosin, [3H]yohimbine, and [3H]nitrendipine) to alpha 1- and alpha 2-adrenergic receptors and calcium channels (Dissociation constants 0.6-6 microM). Verapamil and its structural analogues competed for alpha 1- and alpha 2-adrenergic receptor binding across multiple tissues, whereas diltiazem and nifedipine did not.
Synapse has enriched 10 related papers. Consider them for comparative context: